scholarly article | Q13442814 |
P2093 | author name string | Edgar B | |
Wesseling H | |||
Dunselman PH | |||
Kuntze CE | |||
Scaf AH | |||
P2860 | cites work | Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man | Q70702521 |
Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure | Q71249271 | ||
Dynamic dialysis as a method for studying protein binding. I. Factors affecting the kinetics of dialysis through a cellophane membrane | Q71409528 | ||
Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress | Q34118763 | ||
First-pass elimination. Basic concepts and clinical consequences | Q34257205 | ||
The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration | Q34397660 | ||
Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects | Q34620868 | ||
Extended least squares nonlinear regression: a possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data | Q36610571 | ||
Efficacy of felodipine in congestive heart failure | Q41981403 | ||
The first pass metabolism of nifedipine in man. | Q42531423 | ||
The effect of nisoldipine on apparent liver blood flow and effective renal plasma flow | Q43128643 | ||
The trans-hepatic extraction of nifedipine | Q43229022 | ||
Commentary: a physiological approach to hepatic drug clearance | Q43996648 | ||
Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. | Q52672658 | ||
Felodipine kinetics in healthy men. | Q54117719 | ||
Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. | Q54407139 | ||
Vascular selectivity of felodipine. | Q54457513 | ||
Treatment of essential hypertension with felodipine in combination with a diuretic | Q68877420 | ||
Effects of single and repeated doses of the calcium antagonist felodipine on blood pressure, renal function, electrolytes and water balance, and renin-angiotensin-aldosterone system in hypertensive patients | Q68986268 | ||
Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasma | Q69140789 | ||
Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients | Q69443400 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacokinetics | Q323936 |
heart failure | Q181754 | ||
congestive heart failure | Q19000661 | ||
P304 | page(s) | 45-52 | |
P577 | publication date | 1989-07-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure | |
P478 | volume | 28 |
Q36115910 | Clinical pharmacokinetics of calcium antagonists. An update |
Q38076347 | Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously). |
Q38253565 | Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). |
Q28325479 | Felodipine Clinical Pharmacokinetics |
Q35336765 | Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders |
Q28325222 | Felodipine: A New Dihydropyridine Calcium-Channel Antagonist |
Q44247783 | Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment |
Q34618855 | Racemic therapeutics--ethical and regulatory aspects |
Q71149787 | Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients |